$1.55 Billion is the total value of Camber Capital Management LP's 45 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $101,935,000 | – | 500,000 | +100.0% | 6.59% | – |
| LIVN | New | LIVANOVA PLC | $71,244,000 | – | 1,200,000 | +100.0% | 4.60% | – |
| HCA | New | HCA HOLDINGS INC | $67,630,000 | – | 1,000,000 | +100.0% | 4.37% | – |
| New | REGENERON PHARMACEUTICALS INCput | $54,287,000 | – | 100,000 | +100.0% | 3.51% | – | |
| BKD | New | BROOKDALE SR LIVING INC | $41,535,000 | – | 2,250,000 | +100.0% | 2.68% | – |
| New | CARDIOVASCULAR SYS INC DEL | $38,934,000 | – | 2,575,000 | +100.0% | 2.52% | – | |
| BMY | New | BRISTOL MYERS SQUIBB COput | $34,395,000 | – | 500,000 | +100.0% | 2.22% | – |
| New | ARENA PHARMACEUTICALS INC | $19,950,000 | – | 10,500,000 | +100.0% | 1.29% | – | |
| PTCT | New | PTC THERAPEUTICS INC | $16,200,000 | – | 500,000 | +100.0% | 1.05% | – |
| LDRH | New | LDR HLDG CORP | $13,394,000 | – | 533,400 | +100.0% | 0.87% | – |
| ELOS | New | SYNERON MEDICAL LTD | $11,609,000 | – | 1,505,700 | +100.0% | 0.75% | – |
| New | TARGACEPTS INCnote | $1,685,000 | – | 1,684,799 | +100.0% | 0.11% | – | |
| XLV | New | SELECT SECTOR SPDR TRput | $1,203,000 | – | 16,700 | +100.0% | 0.08% | – |
| New | BIOLASE INCcall | $15,000 | – | 1,841,173 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.